Eisai taps SFJ to speed lenvatinib to market
This article was originally published in Scrip
Eisai has linked with the US/Japan drug development venture SFJ Pharmaceuticals to speed up the development of its pipeline anticancer molecule lenvatinib (E7080) for its lead indication of thyroid cancer.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.